Our findings identify a combinatorial mechanism in which genetic predisposition to enhanced IL-17A signaling, together with gut mycobiome dysbiosis, promotes MASH development and fibrosis progression. This evidence concerns the gene IL17A and metabolic dysfunction-associated steatohepatitis.